Colorectal Cancer

enhertu-for-cancer-treatment-and-management

May 09, 2025

ENHERTU’s Rapid Rise: How the HER2-Targeting ADC Is Redefining Cancer Treatment with Back-to-Back Label Expansions

pharma-news-for-boston-scientific-roche-northstrive

Apr 29, 2025

Boston Scientific Pushes Forward Despite $200M Tariff Challenge; Northstrive Biosciences Gets FDA Green Light to Advance EL-22 Obesity Trial; Roche Acts Swiftly to Offset U.S. Tariff Impact with Global Engagements; Verastem Oncology Secures IND Clearance for KRAS G12D Inhibitor Trial; BlackfinBio Gets FDA OK for Phase I/II Trial of BFB-101 in SPG47

role-of-ai-in-cancer-diagnostics

Nov 27, 2024

AI in Cancer Diagnostics: Paving the Way for Early Detection and Precision Treatment

pharma-news-for-gilead-merck-astellas

Oct 22, 2024

Gilead and Merck Announce Encouraging Phase II Results of Islatravir and Lenacapavir Combo; REGENXBIO Highlights Positive Data from Phase II ABBV-RGX-314 Wet AMD Study at AAO 2024; FDA Greenlights Astellas’ VYLOY for Advanced Gastric and GEJ Cancer Therapy; Merck’s CAPVAXIVE Vaccine Yields Strong Immune Response in Adults Vulnerable to Pneumococcal Disease; FDA Postpones LUMAKRAS Colorectal Cancer Verdict to Early 2025

7-key-companies-developing-trispecific-antibodies

Oct 04, 2024

7 Companies at the Forefront of Trispecific Antibody Development

gastrointestinal-cancers-and-their-types

Oct 02, 2024

Gastrointestinal Cancers: Exploring the Range of Digestive Tract Malignancies

smart-pills-future-outlook

Apr 24, 2024

From Science Fiction to Reality: Investigating the Market Dynamics and Growing Demand for the Smart Pills

egfr-inhibitors-for-cancer-treatment

Mar 29, 2024

Potential of EGFR Inhibitors: A Promising Avenue in Cancer Treatment

Pharma News for Bayer, AstraZeneca, AbbVie, A2 Bio

Mar 05, 2024

Bayer’s New Cardiology Drug Acoramidis; Two Datopotamab Deruxtecan Applications Validated in the EU; AbbVie and OSE Immunotherapeutics Announce Announces Partnership; vTv Therapeutics Makes Major Move With Cadisegliatin; A2 Bio Scores FDA Orphan Drug Designation for its Therapy, A2B530; FDA Fast Track Designation for AlloNK® in Lupus Nephritis

Pharma News for Eisai, Biogen, Merck, BMS, Kyverna

Dec 19, 2023

Eisai Submits Marketing Authorization Application for Tasurgratinib; CHMP Issues Positive Opinion for Biogen’s SKYCLARYS; European Commission Approves Merck’s KEYTRUDA + Chemotherapy HER2-ve Gastric or GEJ Adenocarcinoma; BMS Provides Update on RELATIVITY-123 Trial; Kyverna Therapeutics Granted FDA Fast Track Designation for KYV-101; Verrica and Torii Pharma Announces Positive Top-line Results from a Confirmatory Phase 3 Trial of TO-208

Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper
Toll-like Receptors Agonist
TLR 7 and 8 Agonist
Gene Therapies Whitepaper

Newsletter/Whitepaper